User menu

Key pharmacokinetic parameters of isepamicin in febrile neutropenic cancer patients and in women with acute pelvic inflammatory disease

Bibliographic reference Yombi, Jean Cyr ; Wallemacq, Pierre ; Leal, Teresinha ; Gala, Jean-Luc ; Vandercam, Bernard. Key pharmacokinetic parameters of isepamicin in febrile neutropenic cancer patients and in women with acute pelvic inflammatory disease. In: Journal of chemotherapy (Florence, Italy), Vol. 17, no. 5, p. 521-6 (2005)
Permanent URL http://hdl.handle.net/2078.1/26214
  1. Hare RS, Curr Chemother Infect Dis, 1, 403 (1980)
  2. Jones RN. Isepamicin, J Chemother, 7, S7–S16 (1995)
  3. Miller GH, The most fre-quently occurring aminoglycoside resistance mechanisms: combined results of surveys in eight regions of the world. J Chemother, 7, S17–S30 (1995)
  4. Lin C., Korduba C., Affrime M., Radwanski E., Nomeir A., Batra V., Cutler D., Cayen M. N., Pharmacokinetics and metabolism of 14C-isepamicin in humans following intravenous administration, 10.1128/aac.39.10.2201
  5. Radwanski E, Antimicrob Agents Chemother, 41, 1794 (1997)
  6. Halstenson C E, Kelloway J S, Affrime M B, Lin C C, Teal M A, Shapiro B E, Awni W M, Isepamicin disposition in subjects with various degrees of renal function., 10.1128/aac.35.11.2382
  7. Uematsu T, Int J Clin Pharmacol Ther Toxicol, 31, 606 (1993)
  8. Tod M, Antimicrob Agents Chemother, 40, 983 (1996)
  9. Zeitany R G, El Saghir N S, Santhosh-Kumar C R, Sigmon M A, Increased aminoglycoside dosage requirements in hematologic malignancy., 10.1128/aac.34.5.702
  10. Zaske DE, Am J Obstet Gynecol, 139, 896 (1981)
  11. Leal T, Clin Chem, 37, 1415 (1991)
  12. Sawchuk Ronald J., Zaske Darwin E., Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: Gentamicin in burn patients, 10.1007/bf01086153
  13. Watling Sharon M., Dasta Joseph F., Aminoglycoside Dosing Considerations in Intensive Care Unit Patients, 10.1177/106002809302700319
  14. Lugo Gustavo, Castaneda-Hernandez Gilberto, Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis : , 10.1097/00003246-199705000-00016
  15. DASTA JOSEPH F., ARMSTRONG DEBORAH K., Variability in aminoglycoside pharmacokinetics in critically ill surgical patients : , 10.1097/00003246-198804000-00004
  16. Tod M, Minozzi K, Louchahi J, Cougnard J, Petitjean O. Population pharmacokinetics study of isepamicin in febrile neutropenic patients. [Abstract A 23] 36th Interscience Conference of Antimicrobial Agents and Chemotherapy 1996, Sept 15-18, New Orleans.
  17. Tod Michel, Padoin Christophe, Petitjean Olivier, Clinical Pharmacokinetics and Pharmacodynamics of Isepamicin : , 10.2165/00003088-200038030-00002
  18. Pivot-Dumarest C, Path Biol, 44, 299 (1996)
  19. Kaojarern S, Maoleekoonpairoj S, Atichartakarn V, Pharmacokinetics of amikacin in hematologic malignancies., 10.1128/aac.33.8.1406
  20. Manny RP, Clin Pharm, 5, 626 (1986)
  21. DELPRIORE G, JACKSONSTONE M, SHIM E, GARFINKEL J, EICHMANN M, FREDERIKSEN M, A Comparison of Once-Daily and 8-Hour Gentamicin Dosing in the Treatment of Postpartum Endometritis, 10.1016/0029-7844(96)00054-3
  22. Pennington J. E., Dale D. C., Reynolds H. Y., MacLowry J. D., Gentamicin Sulfate Pharmacokinetics: Lower Levels of Gentamicin in Blood during Fever, 10.1093/infdis/132.3.270
  23. Baylis C, Nephrology. 1st ed., 25 (1997)
  24. Zaske D.E, Aminoglycosides. In: (1992)
  25. Singer Michael A., Of mice and men and elephants: Metabolic rate sets glomerular filtration rate, 10.1016/s0272-6386(01)80073-1
  26. Mackowiak PA, Temperature regulation and the patho-genesis of fever. In:, 703 (2005)
  27. Finley R S, Fortner C L, deJongh C A, Wade J C, Newman K A, Caplan E, Britten J, Wiernik P H, Schimpff S C, Comparison of standard versus pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patients., 10.1128/aac.22.2.193
  28. Moore R. D., Lietman P. S., Smith C. R., Clinical Response to Aminoglycoside Therapy: Importance of the Ratio of Peak Concentration to Minimal Inhibitory Concentration, 10.1093/infdis/155.1.93
  29. Moore R. D., Smith C. R., Lietman P. S., The Association of Aminoglycoside Plasma Levels with Mortality in Patients with Gram-Negative Bacteremia, 10.1093/infdis/149.3.443
  30. Moore Richard D., Smith Craig R., Lietman Paul S., Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia, 10.1016/0002-9343(84)90358-9
  31. Destache CJ, Ther Drug Monit, 12, 623 (1990)
  32. McCormack J. P., Jewesson P. J., A Critical Reevaluation of the "Therapeutic Range" of Aminoglycosides, 10.1093/clinids/14.1.320
  33. Cometta A, Antimicrob Agents Chemother, 40, 1108 (1996)
  34. Kashuba ADM, Antimicrob Agents Chemother, 42, 1842 (1998)
  35. Amsden Guy W, Owens Robert C, Bertino Joseph S, AUIC in Humans: A Fact-Based Discussion, 10.1345/aph.1d337
  36. Schentag J. J., Gilliland K. K., Paladino J. A., What Have We Learned from Pharmacokinetic and Pharmacodynamic Theories?, 10.1086/319375
  37. Kiem S, Why do neutrophils markedly reduce the 24-hr AUC/MIC required for efficacy of fluoro-quinolones against Streptococcus pneumoniae. (abstract 9-492). In: (2002)